Search

Your search keyword '"Dollfus S"' showing total 544 results
Start Over Author "Dollfus S"
544 results on '"Dollfus S"'

1. Auditory verbal hallucinations in schizophrenia: current perspectives in brain stimulation treatments

Author

Nathou C, Etard O, and Dollfus S

Subjects
electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, auditory hallucinations, schizophrenia, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Clément Nathou,1,2 Olivier Etard,2,3 Sonia Dollfus1,21Normandie Univ, UNICAEN, CHU de Caen, Service de Psychiatrie Adulte, Caen, F-14000, France; 2Normandie Univ, UNICAEN, ISTS, EA 7466, GIP Cyceron, Caen 14000, France; 3Normandie Univ, UNICAEN, CHU de Caen, Service des Explorations Fonctionnelles du Système Nerveux, CHU de Caen, Caen, F-14000, FrancePurpose: This review reports the current perspectives of brain stimulation techniques in the treatment of auditory verbal hallucinations (AVH) in schizophrenia.Methods: A systematic search of the literature in the PubMed database revealed that the most studied techniques are noninvasive techniques (NIBS), including electroconvulsive therapy (ECT), transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS).Results: The results showed that ECT could have great clinical efficacy but is currently underused in practice perhaps due to the costs associated with its limited implementation and potential associated risks. tDCS is still poorly studied and does not demonstrate sufficiently homogeneous or conclusive results yet to prove its efficacy in the treatment of AVH. However, its safe and simple implementation allows us to recommend it to patients who are refractory to other stimulation techniques. Finally, rTMS seems to be the most efficacious NIBS to offer patients with persistent AVH as an add-on therapeutic strategy. Its implementation has a non negligible cost but can be performed by a single practitioner. Great evolution in these techniques with technological progress, robotics and computer science are currently being tested and will undoubtedly improve the clinical efficacy of these procedures, particularly towards more personalized treatments such as individual rTMS targets and intensities. There are also new techniques for deep brain stimulation based on focused ultrasound that could provide much insight into the treatment of AVH in schizophrenia.Conclusion: This review suggests that add-on brain stimulation treatments could play a key role among the therapeutic strategies for auditory hallucinations reduction in schizophrenia.Keywords: electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, auditory hallucinations, schizophrenia

Published
2019

19. EPA guidance on assessment of negative symptoms in schizophrenia

Author

Galderisi, S., Mucci, A., Dollfus, S., Nordentoft, M., Falkai, P., Kaiser, S., Giordano, G. M., Vandevelde, A., Nielsen, M., Glenthøj, L. B., Sabé, M., Pezzella, P., Bitter, I., Gaebel, W., Galderisi, S., Mucci, A., Dollfus, S., Nordentoft, M., Falkai, P., Kaiser, S., Giordano, G. M., Vandevelde, A., Nielsen, M., Glenthøj, L. B., Sabé, M., Pezzella, P., Bitter, I., and Gaebel, W.

Abstract

BACKGROUND: During the last decades, a renewed interest for negative symptoms (NS) was brought about by the increased awareness that they interfere severely with real-life functioning, particularly when they are primary and persistent. METHODS: In this guidance paper, we provide a systematic review of the evidence and elaborate several recommendations for the conceptualization and assessment of NS in clinical trials and practice. RESULTS: Expert consensus and systematic reviews have provided guidance for the optimal assessment of primary and persistent negative symptoms; second-generation rating scales, which provide a better assessment of the experiential domains, are available; however, NS are still poorly assessed both in research and clinical settings.This European Psychiatric Association (EPA) guidance recommends the use of persistent negative symptoms (PNS) construct in the context of clinical trials and highlights the need for further efforts to make the definition of PNS consistent across studies in order to exclude as much as possible secondary negative symptoms. We also encourage clinicians to use second-generation scales, at least to complement first-generation ones.The EPA guidance further recommends the evidence-based exclusion of several items included in first-generation scales from any NS summary or factor score to improve NS measurement in research and clinical settings. Self-rated instruments are suggested to further complement observer-rated scales in NS assessment.Several recommendations are provided for the identification of secondary negative symptoms in clinical settings. CONCLUSIONS: The dissemination of this guidance paper may promote the development of national guidelines on negative symptom assessment and ultimately improve the care of people with schizophrenia.

Published
2021

20. EPA guidance on treatment of negative symptoms in schizophrenia

Author

Galderisi, S., Kaiser, S., Bitter, I., Nordentoft, M., Mucci, A., Sabé, M., Giordano, G. M., Nielsen, M., Glenthøj, L. B., Pezzella, P., Falkai, P., Dollfus, S., Gaebel, W., Galderisi, S., Kaiser, S., Bitter, I., Nordentoft, M., Mucci, A., Sabé, M., Giordano, G. M., Nielsen, M., Glenthøj, L. B., Pezzella, P., Falkai, P., Dollfus, S., and Gaebel, W.

Abstract

Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in the conceptualization and assessment is not yet fully reflected by treatment research. Nevertheless, there is a growing evidence base regarding the effects of biological and psychosocial interventions on negative symptoms. The importance of the distinction between primary and secondary negative symptoms for treatment selection might seem evident, but the currently available evidence remains limited. Good clinical practice is recommended for the treatment of secondary negative symptoms. Antipsychotic treatment should be optimized to avoid secondary negative symptoms due to side effects and due to positive symptoms. For most available interventions, further evidence is needed to formulate sound recommendations for primary, persistent, or predominant negative symptoms.However, based on currently available evidence recommendations for the treatment of undifferentiated negative symptoms (including both primary and secondary negative symptoms) are provided. Although it has proven difficult to formulate an evidence-based recommendation for the choice of an antipsychotic, a switch to a second-generation antipsychotic should be considered for patients who are treated with a first-generation antipsychotic. Antidepressant add-on to antipsychotic treatment is an option. Social skills training is recommended as well as cognitive remediation for patients who also show cognitive impairment. Exercise interventions also have shown promise. Finally, access to treatment and to psychosocial rehabilitation should be ensured for patients with negative symptoms. Overall, there is definitive progress in the field, but further research is clearly needed to develop specific treatments for negative symptoms.

Published
2021

22. EPA guidance on assessment of negative symptoms in schizophrenia

Author

Galderisi, S., primary, Mucci, A., additional, Dollfus, S., additional, Nordentoft, M., additional, Falkai, P., additional, Kaiser, S., additional, Giordano, G. M., additional, Vandevelde, A., additional, Nielsen, M. Ø., additional, Glenthøj, L. B., additional, Sabé, M., additional, Pezzella, P., additional, Bitter, I., additional, and Gaebel, W., additional

Published
2021
Full Text
View/download PDF

23. EPA guidance on treatment of negative symptoms in schizophrenia

Author

Galderisi, S., primary, Kaiser, S., additional, Bitter, I., additional, Nordentoft, M., additional, Mucci, A., additional, Sabé, M., additional, Giordano, G. M., additional, Nielsen, M. Ø., additional, Glenthøj, L. B., additional, Pezzella, P., additional, Falkai, P., additional, Dollfus, S., additional, and Gaebel, W., additional

Published
2021
Full Text
View/download PDF

38. Can men be included in the population subjected to puerperal psychosis? A case report

Author

Colombel, M, Rebillard, C, Nathou, C, Dollfus, S, Service de psychiatrie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Imagerie et Stratégies Thérapeutiques de la Schizophrénie (ISTS), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Caen Normandie (UNICAEN), and Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)

Subjects
Male, Father, [SDV]Life Sciences [q-bio], Psychotic disorder, Post-partum period, Antipsychotic agent, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

39. Scale for assessing negative symptoms in schizophrenia: A systematic review

Author

Mach, C, Dollfus, S, Service de psychiatrie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Imagerie et Stratégies Thérapeutiques de la Schizophrénie (ISTS), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), and Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio], Schizophrenia, Scales, Negative symptoms, Assessment, Instruments, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

40. Relation entre la violence intra-hospitalière des patients avec psychoses et la violence dans la communauté

Author

Rothärmel, M., primary, Poirier, M.-F., additional, Levacon, G., additional, Kazour, F., additional, Bleher, S., additional, Gastal, D., additional, Lazareth, S., additional, Lebain, P., additional, Olari, M., additional, Oukebdane, R., additional, Rengade, C.-E., additional, Themines, J., additional, Abbar, M., additional, Dollfus, S., additional, Gassiot, A., additional, Haouzir, S., additional, Januel, D., additional, Millet, B., additional, Olié, J.-P., additional, Stamatiadis, L., additional, Terra, J.-L., additional, Bénichou, J., additional, Campion, D., additional, and Guillin, O., additional

Published
2017
Full Text
View/download PDF

45. Efficacy of high-frequency neuronavigated repetitive TMS in auditory verbal hallucinations: a double-blind controlled study in patients with schizophrenia

Author

Dollfus, S., primary, Jaafari, N., additional, Guillin, O., additional, Trojak, B., additional, Plaze, M., additional, Saba, G., additional, Nauczyciel, C., additional, Montagne Larmurier, A., additional, Chastan, N., additional, Meille, V., additional, Krebs, M., additional, Ayache, S., additional, Lefaucheur, J., additional, Razafimandimby, A., additional, Leroux, E., additional, Morello, R., additional, Nathou, C., additional, and Etard, O., additional

Published
2017
Full Text
View/download PDF

48. Cortical anatomical variations and efficacy of rTMS in the treatment of auditory hallucinations’ Brain stimulation

Author

Nathou, C, Simon, G, Dollfus, S, Etard, O, Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service de psychiatrie [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Laboratoire de psychologie du développement et de l'éducation de l'enfant (LaPsyDÉ - UMR 8240), Normandie Université (NU)-Normandie Université (NU)-Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales ( ISTCT ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Centre National de la Recherche Scientifique ( CNRS ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Service de psychiatrie [Caen], Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Caen, Laboratoire de psychologie du développement et de l'éducation de l'enfant ( LaPsyDÉ - UMR 8240 ), and Normandie Université ( NU ) -Normandie Université ( NU ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
Scalp-to-cortex distance, nervous system, [ SDV ] Life Sciences [q-bio], TMS, [SDV]Life Sciences [q-bio], mental disorders, Schizophrenia, Auditory hallucinations, behavioral disciplines and activities
Abstract

International audience; BACKGROUND:Repetitive transcranial magnetic stimulation (rTMS) shows high inter-subject variability in its efficacy for treating resistant auditory verbal hallucinations in schizophrenia. Currently, the response of an individual patient to rTMS treatment cannot be predicted. It is possible that cortical anatomical characteristics could affect the therapeutic response.OBJECTIVE:We hypothesized that rTMS efficacy is related to anatomical variations underlying the stimulation target in the left temporal cortex. We investigated two regions of interest (ROIs) that have been implicated in rTMS: the left temporal cortex, where the stimulation is delivered, and the primary hand motor cortex, where the stimulation strength is determined by the resting motor threshold (rMT).METHODS:Fifteen patients with schizophrenia (DSM IV) underwent rTMS and magnetic resonance imaging. The scalp-to-cortex distance (SCD) and the grey matter density (GMD) were measured in both ROIs. Linear regression models were used to investigate the relationships between these measures and the clinical efficacy of rTMS.RESULTS:Treatment efficacy was highly predicted by the temporal SCD and the GMD in the temporal and primary hand motor cortex regions. In contrast, the rMT was not predicted by the primary hand motor cortex SCD or GMD.CONCLUSION:These results suggest that rTMS treatment efficacy could be related to the depth of the temporal target. The data raise the question of whether rMT is the best measure for assessing the stimulation intensity in treating patients with schizophrenia.

Published
2015

49. How do high- and low-frequency repetitive transcranial magnetic stimulations modulate the temporal cortex

Author

Nathou, C, Etard, O, SIMON, G, Dollfus, S, Imagerie et Stratégies Thérapeutiques de la Schizophrénie (ISTS), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service de psychiatrie [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service des Explorations Fonctionnelles [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Laboratoire de psychologie du développement et de l'éducation de l'enfant (LaPsyDÉ - UMR 8240), Normandie Université (NU)-Normandie Université (NU)-Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), and Normandie Université (NU)

Subjects
[SDV]Life Sciences [q-bio], Sensory gating, P50, Schizophrenia, ComputingMilieux_MISCELLANEOUS, Transcranial magnetic stimulation
Abstract

International audience

Published
2015

50. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial

Author

Galderisi S., Mucci A., Bitter I., Libiger J., Bucci P., Wolfgang Fleischhacker W., Kahn R. S., Fleischhacker W. W., Boter H., Keet I. P. M., Brugman C., Davidson M., Dollfus S., Gaebel W., Gheorghe M., Gonen I., Grobbee D. E., Hranov L. G., Hummer M., Lindefors N., Lopez-Ibor J. J., Nijssen K., Peuskens J., Prelipceanu D., Riecher-Rossler A., Rybakowski J. K., Sedvall G., Von Wilmsdorff M., Galderisi, S., Mucci, A., Bitter, I., Libiger, J., Bucci, P., Wolfgang Fleischhacker, W., Kahn, R. S., Fleischhacker, W. W., Boter, H., Keet, I. P. M., Brugman, C., Davidson, M., Dollfus, S., Gaebel, W., Gheorghe, M., Gonen, I., Grobbee, D. E., Hranov, L. G., Hummer, M., Lindefors, N., Lopez-Ibor, J. J., Nijssen, K., Peuskens, J., Prelipceanu, D., Riecher-Rossler, A., Rybakowski, J. K., Sedvall, G., and Von Wilmsdorff, M.

Subjects
Male, Pediatrics, Neuropsychological Tests, Cognitive functioning, Piperazines, Psychomotor Disorder, Benzodiazepines, Pharmacology (medical), Duration of untreated psychosi, Depression (differential diagnoses), First episode, Benzodiazepine, Parkinsonism, Dibenzothiazepine, Psychiatry and Mental health, Treatment Outcome, Neurology, Schizophrenia, Olanzapine, Neuropsychological Test, Female, Schizophrenic Psychology, Amisulpride, Psychology, Human, Psychopathology, medicine.drug, Antipsychotic Agents, Quality of life, Adult, medicine.medical_specialty, Dibenzothiazepines, Adolescent, Remission, Psychotic Disorder, Cognition Disorder, Quetiapine Fumarate, Young Adult, medicine, Humans, Psychiatry, Piperazine, Biological Psychiatry, Pharmacology, medicine.disease, Global functioning, Discontinuation, Thiazoles, Antipsychotic Agent, nervous system, Psychotic Disorders, dup, Haloperidol, Neurology (clinical), Thiazole, Psychomotor Disorders, Sulpiride, Cognition Disorders
Abstract

Negative symptoms that do not improve following antipsychotic treatment represent a challenge for development of effective treatments. Few studies have been carried out so far, especially in first-episode schizophrenia patients, to clarify prevalence, correlates and impact of persistent negative symptoms (PNS) on short- and long-term outcome of the disease.All patients from EUFEST study for whom both baseline and 12-month assessments were available were included (N=345). PNS were defined as the presence of at least one negative symptom of moderate or higher severity, not confounded by depression or parkinsonism, at baseline and after 1 year of treatment. Patients with PNS were compared to those with at least one negative symptom of moderate or higher severity at the baseline, not persisting after 1 year, on demographic, clinical, neurocognitive, global functioning and quality of life measures.PNS not confounded by depression or parkinsonism were present in 6.7% of the sample. The symptom that more often persisted was blunted affect. Patients with PNS differed from those without PNS for a longer duration of untreated psychosis (DUP) and a more frequent discontinuation of study treatment; they also had a poorer psychopathological outcome and a worse global functioning after 1 year of treatment.The presence of PNS was associated to poorer improvement of all psychopathological dimensions and worse global functioning after 1 year of treatment. The longer DUP in subjects with PNS suggests that programs aimed at shortening DUP might reduce the prevalence of PNS and improve prognosis of schizophrenia. © 2012 Elsevier B.V. and ECNP.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results